Organization (Industry)
3M COMPANY
ClinicalTrials.gov lists 3M COMPANY as lead sponsor of 12 trials, counting the companies grouped under it. 3M COMPANY itself has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Stephen Dunne of Siegel & Gale, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers 3M COMPANY and 1 company grouped under it: 12 lead-sponsored trials (12 its own, 0 in the grouped companies) and 11 legal-entity registrations (10 its own, 1 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| 3M Deutschland GmbH | 0 | 1 |
Disease areas (64)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dental Caries | 8 |
| Hypothermia | 7 |
| Respiratory Aspiration | 5 |
| Surgical Wound | 5 |
| Surgical Wound Infection | 5 |
Showing 5 of 64 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 7 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 12 |
| 2016 | 9 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ChloraPrep | 1 |
| Povidone iodine | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=7) | 40% on time (n=5) |
Journals published in (151)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of surgery | 6 |
| Critical care medicine | 6 |
| American journal of infection control | 5 |
| Infection control and hospital epidemiology | 5 |
| International wound journal | 5 |
Showing 5 of 151 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7,929 | 0 | 2006-11-07 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 24,948,000,000 | 3,250,000,000 | not reported |
| 2024 | 24,575,000,000 | 4,173,000,000 | 700,000,000 |
| 2023 | 24,610,000,000 | -6,995,000,000 | 700,000,000 |
| 2022 | 26,161,000,000 | 5,777,000,000 | 800,000,000 |
| 2021 | 35,355,000,000 | 5,921,000,000 | 1,200,000,000 |
| 2020 | 32,184,000,000 | 5,449,000,000 | 1,100,000,000 |
| 2019 | 32,136,000,000 | 4,517,000,000 | 1,253,000,000 |
| 2018 | 32,765,000,000 | 5,349,000,000 | 1,253,000,000 |
| 2017 | 31,657,000,000 | 4,858,000,000 | 1,352,000,000 |
| 2016 | 30,109,000,000 | 5,050,000,000 | 1,248,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-30 | Debt financing | not disclosed | Sec extracted |
| 2026-02-03 | Follow-on offering | not disclosed | Edgar offerings |
| 2025-03-13 | Debt financing | 1,100,000,000 | Sec extracted |
| 2025-03-05 | Debt financing | 1,099,323,500 | Edgar offerings |
| 2025-03-04 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 40 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| 3M Ranger Irrigation Fluid Warming Set, REF 24750 | Class II | 2025-04-22 |
| 3M Ranger Blood/Fluid Warming High Flow Set Catalog Numbers 24355, 24370 | Class I | 2025-04-10 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 37 | 2025-09-19 |
Manufacturing and distribution sites (6)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| 3M COMPANY | Saint Paul, US | FDA | |
| 3M COMPANY | ABERDEEN, US | FDA | |
| 3M COMPANY | BROOKINGS, US | FDA | |
| 3M Company | Cordova, US | FDA | |
| 3M COMPANY | Valley, US | FDA |
Showing 5 of 6 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Cologne | Co sponsors trial with | 1 |
| University of Alberta | Co sponsors trial with | 1 |
| Wake Forest University | Co sponsors trial with | 1 |
| Alberta Health Services | Co sponsors trial with | 1 |
| National Alopecia Areata Foundation | Co sponsors trial with | 1 |
Showing 5 of 16 relationships.
Latest dated events (8,161)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-24 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-30 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-03 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-19 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-04-22 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 8,161 events.
CLIA clinical laboratory certificates (6)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| 3M | Certificate of waiver | Active |
| 3M | Certificate of waiver | Active |
| 3M COMPANY | Certificate of waiver | Active |
| 3M | Certificate of waiver | Active |
| 3M | Certificate of waiver | Terminated |
Showing 5 of 6 certificates.
Biomarker capability evidence (11)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial collaborator | Named in trial exclusion criteria |
| F2 | Trial collaborator | Named in trial exclusion criteria |
| F3 | Trial collaborator | Named in trial exclusion criteria |
| FGF7 | Trial collaborator | Named in trial exclusion criteria |
| PTGS2 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 11 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: active development programs, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.